Interventional Oncology Devices – Market Insights – Asia Pacific

The Asia Pacific interventional oncology device market will see strong growth through 2034, driven by updated clinical guidelines, broader access to minimally invasive cancer treatments, and growing physician confidence in ablation and embolization. Adoption of premium-priced devices will be supported by positive clinical trial data, unmet demand in China and India, and changing modality preferences in liver and lung tumor ablation. However, growth will be limited by reimbursement gaps, cost sensitivity, and competition from domestic manufacturers. Additionally, the Chinese interventional oncology device market will go through a shift after the implementation of VBP for these devices.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for interventional oncology devices in the Asia Pacific region from 2019 to 2034.

Growing access and increased demand for minimally invasive cancer treatments are fueling the Asia Pacific interventional oncology device market’s acceleration.

How is the need for targeted interventional therapy being impacted by the increased prevalence of kidney, lung, and liver cancers?

How are referral patterns for interventional therapy being impacted by multidisciplinary oncology teams?

The underpenetrated Indian and Chinese interventional oncology device markets have strong growth potential.

What are the factors responsible for the underpenetration of Indian and Chinese interventional oncology device markets?

How are the clinical guidelines impacting various device segments in these countries?

Reimbursement will be a crucial factor in the adoption of interventional oncology procedures in the cost-conscious Asia Pacific region.

What is the reimbursement scenario in the Asia Pacific region?

How will reimbursement availability impact the interventional oncology device market in future?

How is the use of premium interventional oncology consumables being influenced by the reimbursement changes in Australia and South Korea?

What impact does cost sensitivity have on hospitals’ and doctors’ preferences for local versus foreign equipment vendors in emerging markets?

China’s centralized procurement measures will impact the overall interventional oncology device market.

What are the major changes in the ASPs of various ablation, embolization, and accessory devices after the implementation of VBP?

How has the market shifted due to bulk volume procurement following VBP implementation for interventional oncology devices?

Positive clinical data will play a key role in driving the adoption of interventional oncology devices, especially the premium-priced devices such as radioembolization spheres and DEBs.

Which clinical trials were recently conducted in this market?

What is the expected impact of these clinical trials on the market dynamics?

Increasing influence of domestic manufacturers in the Asia Pacific interventional oncology device market will change market dynamics in the future.

What are the major demographic, economic, and local trend differences across the Asia Pacific region that impact the adoption of and demand for these devices?

What are the distribution strategies employed by competitors to position themselves in this market, and what challenges do they face?

In what ways are local competitors using cost and production advantages to compete with foreign suppliers in the embolization and ablation device markets?

What is the current competitive landscape of the market, and how will it change over the forecast period?

Ablation therapy procedures will continue to grow for the liver, kidney, and lung cancer indications and will witness change in adoption trends for different ablation modalities over the forecast period.

How will market growth vary across different ablation device categories?

What factors are driving the uptake of different ablation device categories across the Asia Pacific market?

How does the uptake of microwave ablation devices affect other types of ablation devices, such as RF ablation devices, and how are competitors preparing for this shift?

What factors are affecting the adoption of IRE ablation devices in the Asia Pacific region.